Prelude Therapeutics IncNASDAQ:PRLD
- LAST PRICE7.0200
- TODAY'S CHANGE (%)-0.3200 (-4.3597%)
- Bid / Lots5.0000/ 1
- Ask / Lots10.4800/ 1
- Open / Previous Close7.2450 / 7.3400
- Day Range
- 52 Week Range
- Volume93,323
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRLD |
|---|---|---|
| 09:32 ET | 4473 | 7.2 |
| 09:33 ET | 200 | 7.19 |
| 09:39 ET | 2000 | 6.8801 |
| 09:42 ET | 4600 | 7.27 |
| 09:50 ET | 203 | 7.27 |
| 09:51 ET | 200 | 7.2 |
| 09:55 ET | 200 | 7.295 |
| 09:57 ET | 2800 | 7.085 |
| 10:00 ET | 300 | 7.28 |
| 10:02 ET | 100 | 7.28 |
| 10:04 ET | 300 | 7.13 |
| 10:13 ET | 425 | 7.3 |
| 10:15 ET | 500 | 7.37 |
| 10:18 ET | 995 | 7.45 |
| 10:22 ET | 800 | 7.485 |
| 10:26 ET | 100 | 7.485 |
| 10:27 ET | 100 | 7.5499 |
| 10:36 ET | 3280 | 7.6 |
| 10:40 ET | 725 | 7.6 |
| 10:42 ET | 100 | 7.55 |
| 10:44 ET | 900 | 7.59 |
| 10:45 ET | 400 | 7.61 |
| 10:56 ET | 2040 | 7.59 |
| 11:00 ET | 900 | 7.55 |
| 11:02 ET | 6200 | 7.45 |
| 11:03 ET | 200 | 7.375 |
| 11:18 ET | 100 | 7.375 |
| 11:20 ET | 300 | 7.38 |
| 11:25 ET | 100 | 7.385 |
| 11:59 ET | 1300 | 7.375 |
| 12:01 ET | 2125 | 7.4 |
| 12:03 ET | 4071 | 7.48 |
| 12:08 ET | 100 | 7.45 |
| 12:15 ET | 200 | 7.46 |
| 12:17 ET | 100 | 7.47 |
| 12:19 ET | 100 | 7.48 |
| 12:21 ET | 3000 | 7.49 |
| 12:30 ET | 3335 | 7.42 |
| 12:39 ET | 300 | 7.33 |
| 01:11 ET | 4774 | 7.16 |
| 01:13 ET | 100 | 7.2 |
| 01:15 ET | 100 | 7.22 |
| 01:18 ET | 505 | 7.15 |
| 01:26 ET | 100 | 7.125 |
| 01:27 ET | 100 | 7.08 |
| 01:42 ET | 125 | 7.11 |
| 01:44 ET | 700 | 7.02 |
| 01:45 ET | 100 | 7.05 |
| 01:49 ET | 1840 | 7.055 |
| 01:51 ET | 1033 | 7.04 |
| 01:54 ET | 200 | 7.04 |
| 01:56 ET | 100 | 7.04 |
| 01:58 ET | 700 | 7.03 |
| 02:00 ET | 189 | 7.03 |
| 02:02 ET | 600 | 7.06 |
| 02:03 ET | 125 | 7.06 |
| 02:05 ET | 402 | 7.08 |
| 02:18 ET | 1100 | 7.03 |
| 02:20 ET | 1100 | 6.995 |
| 02:23 ET | 100 | 6.995 |
| 02:34 ET | 400 | 7 |
| 02:52 ET | 400 | 6.98 |
| 02:54 ET | 3093 | 7.025 |
| 03:06 ET | 1782 | 7.045 |
| 03:12 ET | 100 | 6.975 |
| 03:15 ET | 300 | 6.96 |
| 03:26 ET | 100 | 7 |
| 03:28 ET | 173 | 7.04 |
| 03:37 ET | 569 | 7.02 |
| 03:44 ET | 200 | 7.02 |
| 03:55 ET | 1300 | 7.04 |
| 03:57 ET | 300 | 7.04 |
| 04:00 ET | 2400 | 7.02 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prelude Therapeutics Inc | 351.3M | -2.8x | --- |
Tyra Biosciences Inc | 350.2M | -6.8x | --- |
Annexon Inc | 352.9M | -2.2x | --- |
Pharvaris NV | 324.5M | -5.2x | --- |
Aldeyra Therapeutics Inc | 356.0M | -5.5x | --- |
Vor Biopharma Inc | 357.3M | -2.3x | --- |
Company Information
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. The Company’s product candidate pipeline includes PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT3645. PRT543 is in a Phase I clinical trial in advanced solid tumors and select myeloid malignancies. PRT811 is a being studied in a Phase I clinical trial in unselected patients with solid tumors, including high-grade glioma. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is designed to be a potent and selective Cyclin-dependent kinase 9 (CDK9), inhibitor. The Company’s drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders.
Contact Information
- Headquarters
- 200 Powder Mill RoadWILMINGTON, DE, United States 19803
- Phone
- 302-467-1280
- Fax
- 302-658-3989
Executives
- Independent Chairman of the Board
- Paul Friedman
- President, Chief Medical Officer
- Jane Huang
- Chief Executive Officer, Founder, Director
- Krishna Vaddi
- Chief Financial Officer
- Laurent Chardonnet
- Executive Vice President, Head of Chemistry
- Andrew Combs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $351.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 47.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.54 |
Book Value | $6.01 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
